ENFLONSIA™ (clesrovimab)
搜索文档
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
Businesswire· 2026-02-19 18:15
公司产品研发进展 - 默克公司宣布了其药物ENFLONSIA (clesrovimab) 针对两岁以下婴幼儿在连续两个呼吸道合胞病毒季节的积极新数据 [1] - 该药物针对的是有严重RSV疾病高风险的婴幼儿群体 [1] 行业疾病领域动态 - 呼吸道合胞病毒是婴幼儿中导致严重下呼吸道感染的主要病因之一，存在明确的未满足临床需求 [1]
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
Businesswire· 2025-09-19 18:50
药品监管进展 - 默沙东ENFLONSIA(clesrovimab)获得欧盟CHMP积极意见 用于预防婴儿首个呼吸道合胞病毒季节的RSV感染 [1] 产品适应症 - 该药物针对呼吸道合胞病毒(RSV)的预防性治疗 目标人群为首次面临RSV感染季节的婴儿群体 [1]